Patent directory · USPTO A61K / A61P
Patents matching “inhibitors”
2,466 pharma patents match "inhibitors" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.
Quick answer
This filtered view shows 2,466 pharmaceutical patents matching "inhibitors" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.
Patent results
-
US 10040769
HDAC inhibitors for the treatment of diabetic peripheral neuropathy
granted -
US 10039802
Methods of treating chronic disorders with complement inhibitors
granted -
US 10039762
Inhibitors of influenza viruses replication
granted -
US 10035824
Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
granted -
US 10028960
Pyrimidine compounds as JAK kinase inhibitors
granted -
US 10029988
HDAC inhibitors
granted -
US 10030024
Imidazopyridazines useful as inhibitors of the PAR-2 signaling pathway
granted -
US 10023569
Methods of preparing inhibitors of influenza viruses replication
granted -
US 10022364
Methods of treating cancer patients with farnesyltransferase inhibitors
granted -
US 10023614
Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
granted -
US 10022382
RNA polymerase I inhibitors and uses thereof
granted -
US 10017516
BMP inhibitors and methods of use thereof
granted -
US 10011574
Glutaminase inhibitors and method of use
granted -
US 10005777
Protein kinase C inhibitors and uses thereof
granted -
US 10005740
Neprilysin inhibitors
granted -
US 10005735
Inhibitors of RPN11
granted -
US 9999650
Peptide and peptidomimetic inhibitors
granted -
US 9994547
Heteroarylamide inhibitors of TBK1
granted -
US 9988397
ERK inhibitors
granted -
US 9987284
Substituted benzooxadiazole DNA-PK inhibitors
granted -
US 9981944
GDF-8 inhibitors
granted -
US 9981961
Deoxycytidine kinase inhibitors
granted -
US 9981999
Neprilysin inhibitors
granted -
US 9980976
Use of REDD1 inhibitors to dissociate therapeutic and adverse atrophogenic effects of glucocorticoid receptor agonists
granted